RU2013127115A - Комбинированная терапия при в-клеточных лимфомах - Google Patents
Комбинированная терапия при в-клеточных лимфомах Download PDFInfo
- Publication number
- RU2013127115A RU2013127115A RU2013127115/15A RU2013127115A RU2013127115A RU 2013127115 A RU2013127115 A RU 2013127115A RU 2013127115/15 A RU2013127115/15 A RU 2013127115/15A RU 2013127115 A RU2013127115 A RU 2013127115A RU 2013127115 A RU2013127115 A RU 2013127115A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- combination therapy
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title claims abstract 17
- 208000003950 B-cell lymphoma Diseases 0.000 title claims abstract 7
- 238000000034 method Methods 0.000 claims abstract 24
- 230000000259 anti-tumor effect Effects 0.000 claims abstract 10
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims abstract 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims abstract 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims abstract 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract 2
- 230000005764 inhibitory process Effects 0.000 claims abstract 2
- 230000003211 malignant effect Effects 0.000 claims abstract 2
- 230000002195 synergetic effect Effects 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 230000004614 tumor growth Effects 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41377110P | 2010-11-15 | 2010-11-15 | |
| US61/413,771 | 2010-11-15 | ||
| PCT/US2011/060520 WO2012067981A1 (en) | 2010-11-15 | 2011-11-14 | Combination therapy for b cell lymphomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013127115A true RU2013127115A (ru) | 2014-12-27 |
Family
ID=46084355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013127115/15A RU2013127115A (ru) | 2010-11-15 | 2011-11-14 | Комбинированная терапия при в-клеточных лимфомах |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130330328A1 (enExample) |
| EP (1) | EP2640416A4 (enExample) |
| JP (1) | JP2013543869A (enExample) |
| KR (1) | KR20130130726A (enExample) |
| CN (1) | CN103228291A (enExample) |
| AU (1) | AU2011329161A1 (enExample) |
| CA (1) | CA2817842A1 (enExample) |
| MX (1) | MX2013005270A (enExample) |
| RU (1) | RU2013127115A (enExample) |
| SG (1) | SG190254A1 (enExample) |
| WO (1) | WO2012067981A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100291T1 (it) * | 2016-05-30 | 2021-07-12 | Morphosys Ag | Metodi per prevedere il beneficio terapeutico di una terapia anti-cd19 in pazienti |
| CN110945028B (zh) * | 2017-07-10 | 2023-09-08 | 国际药物发展生物技术公司 | 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤 |
| RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006089133A2 (en) * | 2005-02-15 | 2006-08-24 | Duke University | Anti-cd19 antibodies and uses in oncology |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| CN103694349A (zh) * | 2006-09-08 | 2014-04-02 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
-
2011
- 2011-11-14 JP JP2013538963A patent/JP2013543869A/ja active Pending
- 2011-11-14 MX MX2013005270A patent/MX2013005270A/es unknown
- 2011-11-14 US US13/885,219 patent/US20130330328A1/en not_active Abandoned
- 2011-11-14 RU RU2013127115/15A patent/RU2013127115A/ru not_active Application Discontinuation
- 2011-11-14 AU AU2011329161A patent/AU2011329161A1/en not_active Abandoned
- 2011-11-14 CN CN2011800548133A patent/CN103228291A/zh active Pending
- 2011-11-14 SG SG2013036512A patent/SG190254A1/en unknown
- 2011-11-14 KR KR1020137012967A patent/KR20130130726A/ko not_active Withdrawn
- 2011-11-14 EP EP11841807.8A patent/EP2640416A4/en not_active Withdrawn
- 2011-11-14 WO PCT/US2011/060520 patent/WO2012067981A1/en not_active Ceased
- 2011-11-14 CA CA2817842A patent/CA2817842A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013005270A (es) | 2013-10-25 |
| JP2013543869A (ja) | 2013-12-09 |
| EP2640416A1 (en) | 2013-09-25 |
| US20130330328A1 (en) | 2013-12-12 |
| AU2011329161A1 (en) | 2013-06-27 |
| SG190254A1 (en) | 2013-06-28 |
| EP2640416A4 (en) | 2014-04-23 |
| KR20130130726A (ko) | 2013-12-02 |
| CN103228291A (zh) | 2013-07-31 |
| CA2817842A1 (en) | 2012-05-24 |
| WO2012067981A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2731548T3 (es) | Composiciones que comprenden anticuerpos anti-CD38 y lenalidomida | |
| EP2648747B1 (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib | |
| CN103118706B (zh) | 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl | |
| JP2023058502A (ja) | 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用 | |
| US12194095B2 (en) | Combinations and uses thereof | |
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| ES2808565T3 (es) | Composiciones que comprenden anticuerpos anti-CD38 y carfilzomib | |
| JP2017528462A5 (enExample) | ||
| FI3778641T3 (fi) | Bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:tä, ja niiden käyttöjä | |
| KR102115203B1 (ko) | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 | |
| JP2014525926A5 (enExample) | ||
| RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах | |
| JP2013543869A5 (enExample) | ||
| HK40069168A (en) | Combinations and uses thereof | |
| RU2021128914A (ru) | Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований | |
| TW201315461A (zh) | 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之抗腫瘤組合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160314 |